Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 8
2003 7
2004 18
2005 14
2006 11
2007 7
2008 17
2009 9
2010 7
2011 20
2012 12
2013 12
2014 16
2015 13
2016 14
2017 19
2018 14
2019 21
2020 18
2021 14
2022 20
2023 21
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

280 results

Results by year

Filters applied: . Clear all
Page 1
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulović S, Demey W, Ullén A, Loriot Y, Sridhar SS, Tsuchiya N, Kopyltsov E, Sternberg CN, Bellmunt J, Aragon-Ching JB, Petrylak DP, Laliberte R, Wang J, Huang B, Davis C, Fowst C, Costa N, Blake-Haskins JA, di Pietro A, Grivas P. Powles T, et al. Among authors: tsuchiya n. N Engl J Med. 2020 Sep 24;383(13):1218-1230. doi: 10.1056/NEJMoa2002788. Epub 2020 Sep 18. N Engl J Med. 2020. PMID: 32945632 Clinical Trial.
This issue 30-4.
Tsuchiya N. Tsuchiya N. Int J Urol. 2023 Apr;30(4):339. doi: 10.1111/iju.15174. Int J Urol. 2023. PMID: 37002906 No abstract available.
This Issue 30-9.
Tsuchiya N. Tsuchiya N. Int J Urol. 2023 Sep;30(9):695. doi: 10.1111/iju.15275. Int J Urol. 2023. PMID: 37710366 No abstract available.
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.
Sridhar SS, Powles T, Climent Durán MÁ, Park SH, Massari F, Thiery-Vuillemin A, Valderrama BP, Ullén A, Tsuchiya N, Aragon-Ching JB, Gupta S, Petrylak DP, Bellmunt J, Wang J, Laliberte RJ, di Pietro A, Costa N, Grivas P, Sternberg CN, Loriot Y. Sridhar SS, et al. Among authors: tsuchiya n. Eur Urol. 2024 Feb;85(2):154-163. doi: 10.1016/j.eururo.2023.08.001. Epub 2023 Sep 14. Eur Urol. 2024. PMID: 37714742 Free article. Clinical Trial.
This issue 31-4.
Tsuchiya N. Tsuchiya N. Int J Urol. 2024 Apr;31(4):306. doi: 10.1111/iju.15443. Int J Urol. 2024. PMID: 38623996 No abstract available.
Refractory laryngeal papillomatosis requiring total laryngectomy.
Nishida H, Yamagishi A, Noda D, Kurakami K, Kabasawa T, Tsuchiya N. Nishida H, et al. Among authors: tsuchiya n. Lancet Infect Dis. 2020 Jul;20(7):874. doi: 10.1016/S1473-3099(20)30057-8. Lancet Infect Dis. 2020. PMID: 32592680 No abstract available.
Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial.
Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M; SNiP-RCC investigators. Shiota M, et al. Among authors: tsuchiya n. Cancer Immunol Immunother. 2023 Jun;72(6):1903-1915. doi: 10.1007/s00262-023-03367-w. Epub 2023 Feb 2. Cancer Immunol Immunother. 2023. PMID: 36729213
Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis.
Lee JL, Desai C, Park SH, Tsuchiya N, Su PJ, Chan TTW, Gurney H, Gao S, Wang J, Sandner R, di Pietro A, Eto M. Lee JL, et al. Among authors: tsuchiya n. Urol Oncol. 2023 May;41(5):256.e17-256.e25. doi: 10.1016/j.urolonc.2023.02.002. Epub 2023 Apr 3. Urol Oncol. 2023. PMID: 37019764 Free article. Clinical Trial.
GPI-80 Augments NF-κB Activation in Tumor Cells.
Takeda Y, Kurota Y, Kato T, Ito H, Araki A, Nara H, Saitoh S, Tanaka N, Tsuchiya N, Asao H. Takeda Y, et al. Among authors: tsuchiya n. Int J Mol Sci. 2021 Nov 6;22(21):12027. doi: 10.3390/ijms222112027. Int J Mol Sci. 2021. PMID: 34769456 Free PMC article.
280 results